Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avastin Data, Policy Implications Warrant Hearing On Breast Cancer Use, Genentech Tells FDA

Executive Summary

Genentech has come out fighting on multiple fronts in its attempt to retain Avastin’s breast cancer indication, proposing a new confirmatory study, submitting new Phase IV data and attacking FDA’s interpretation of both the underlying scientific data and its regulations on withdrawal.
Advertisement

Related Content

Genentech Banking On Biomarker Data To Save Avastin In Breast Cancer
Genentech Banking On Biomarker Data To Save Avastin In Breast Cancer
An Avastin Loophole: Hamburg Could Decide To Retain Approval During Confirmatory Trial
Avastin Hearing's Deadline For Written Submissions Is Indefinitely Delayed
Genentech Asks A Lot From Avastin Hearing
Deals Of The Week: Ironwood/Protagonist, Merck Serono/Domain, Pfizer/Theraclone
Genentech May Not Get A Chance To Appeal FDA's Decision To Withdraw Avastin's Breast Cancer Approval
Genentech May Not Get A Chance To Appeal FDA's Decision To Withdraw Avastin's Breast Cancer Approval
How The Avastin Appeal Will Proceed
Avastin Down, But Not Out Yet In Metastatic Breast Cancer Indication

Topics

Advertisement
UsernamePublicRestriction

Register

PS053058

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel